Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Rating of “Buy” from Analysts

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been given a consensus rating of “Buy” by the eleven brokerages that are covering the company, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $58.20.

A number of research firms have issued reports on MIRM. Robert W. Baird upped their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a report on Thursday, February 27th. HC Wainwright increased their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, February 28th.

Mirum Pharmaceuticals Price Performance

Shares of MIRM stock opened at $47.02 on Tuesday. The stock’s 50 day simple moving average is $47.95 and its 200 day simple moving average is $43.75. Mirum Pharmaceuticals has a twelve month low of $23.14 and a twelve month high of $54.23. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The company has a market capitalization of $2.30 billion, a price-to-earnings ratio of -23.28 and a beta of 1.04.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. As a group, research analysts predict that Mirum Pharmaceuticals will post -1.43 EPS for the current year.

Insider Activity

In other news, SVP Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $32,115.00. Following the completion of the transaction, the senior vice president now owns 2,926 shares in the company, valued at approximately $125,291.32. The trade was a 20.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Peter Radovich sold 1,998 shares of the business’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36. Following the completion of the transaction, the chief operating officer now directly owns 27,015 shares of the company’s stock, valued at approximately $1,156,782.30. This represents a 6.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 133,679 shares of company stock worth $6,007,081. Corporate insiders own 22.87% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp boosted its position in Mirum Pharmaceuticals by 19.9% in the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after buying an additional 297,511 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Mirum Pharmaceuticals by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock worth $12,798,000 after acquiring an additional 17,149 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Mirum Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock valued at $36,519,000 after acquiring an additional 29,017 shares during the period. Hennion & Walsh Asset Management Inc. boosted its holdings in Mirum Pharmaceuticals by 25.5% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company’s stock valued at $6,021,000 after acquiring an additional 29,545 shares during the last quarter. Finally, AlphaQuest LLC increased its position in Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock worth $76,000 after purchasing an additional 1,658 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.